What Has Been The Evolution of the Angina Pectoris Drugs Market in Recent Years?
The angina pectoris drugs market has seen considerable growth due to a variety of factors.
•The market for angina pectoris medications has seen robust growth in recent times. The market is forecasted to expand from $12.32 billion in 2024 to $12.94 billion in 2025, with a compound annual growth rate (CAGR) of 5.1%.
This growth observed in the historical period has been driven by factors such as the high occurrence of cardiovascular diseases, changing age demographics, lifestyle influences, rising rates of hypertension, and the growing prevalence of diabetes.
What Is the Forecasted Market Size and Growth Rate for The Angina Pectoris Drugs Market?
The angina pectoris drugs market is expected to maintain its strong growth trajectory in upcoming years.
• There is an expected robust expansion in the angina pectoris drugs market in the coming years. Predictions indicate it will reach "$16.55 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%.
The forecasted period's growth can be linked to surging obesity levels worldwide, advancements in precision medicine, an emphasis on preventive cardiology, efforts in patient education, and new therapeutic target research. Prevailing trends during the forecasted period involve the use of telemedicine for distant patient monitoring, real-world evidence and outcome research, patient-focused medication learning, strategic collaborations for market entry, regulatory progression, and fast-tracked approvals.
What Factors Are Driving Growth In The Angina Pectoris Drugs Market?
The escalating incidence of cardiovascular disorders is anticipated to fuel the expansion of the angina pectoris drug market. Conditions like coronary artery disease, high blood pressure, heart failure, and stroke, which affect the heart and blood vessels, fall under the blanket term of cardiovascular diseases. The rising incidence of these disorders can be linked to various factors including an older population, unhealthy living habits and a growing obesity crisis. Medications for angina pectoris, such as nitrates, beta-blockers, and calcium channel blockers, efficiently soothe the chest pain and discomfort resulting from inadequate blood supply to the heart, thereby improving the overall patient's quality of life. For instance, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that in the UK, an estimated 7.6 million people suffer from heart and circulatory diseases, with approximately 4 million males and 3.6 million females grappling with these conditions. These diseases account for roughly 27% of all deaths in the UK, leading to over 170,000 deaths every year, or about 480 deaths daily, which means one death every three minutes. Consequently, the escalating incidence of cardiovascular diseases is propelling the expansion of the angina pectoris drug market.
What Are The Main Segments Of The Global Angina Pectoris Drugs Market?
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Pre-Book The Angina Pectoris Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Angina Pectoris Drugs Market?
The adoption of product innovation is increasingly becoming a critical trend within the angina pectoris drugs market. To maintain their market standing, main companies trading in this particular drug market are resorting to new technological advancements. As a case in point, Hikma Pharmaceuticals PLC, which is a UK-situated pharmaceutical establishment, introduced the Labetalol Hydrochloride Injection, USP, in a predosed syringe in March 2023. This product has been granted approval by the United States Food and Drug Administration. The application of 10mg/2 mL PFS within hospital settings serves the purpose of managing severe hypertension and reducing blood pressure levels.
Who Are the Key Players in the Angina Pectoris Drugs Market?
Major companies operating in the angina pectoris drugs market include:
• Astellas Pharma Inc.
• Bayer AG
• Novartis AG
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Merck & Co Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Abbott Laboratories
• Sun Pharmaceutical Industries Limited
• Sanofi SA
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson
• AERIE PHARMACEUTICALS INC.
• AbbVie Inc.
• Amgen Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Ipsen S.A.
• Lupin Pharmaceuticals Inc.
• Merck KGaA
• Otsuka Pharmaceutical Co. Ltd.
• Regeneron Pharmaceuticals Inc.
• Servier Laboratories
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
What Is The Most Dominant Region In The Angina Pectoris Drugs Market?
North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
